68Ga-DOTA PET-CT in Treatment Response Evaluation: Neuroendocrine Tumours

Neuroendocrine tumors (NET) are relatively rare disorders that more often present as well-differentiated tumors with a relatively good prognosis. According to recent EANM/ENETS guidelines, treatment response should be assessed with morphologic RECIST criteria. However, it is well known that they present several limitations in NET assessment (mostly concerning the relatively small variations in the size of generally slow-growing disorders and the difficult evaluation of the cystic component). Moreover, PET/CT can often detect functional changes indicative of active disease before morphological changes become apparent on CT. Combined functional and morphological imaging might, in many cases, better reflect the real behavior of the tumor following treatment.